The PD-L1-related miRNA profile has been shown to have the potential to predict the response of lung squamous cell carcinoma (LUSC) patients to PD-L1/PD-1 inhibitors, helping identify the optimal treatment cohort [35]. This evidence concerns the gene CD274 and squamous cell lung carcinoma.